FIG 6.

Clinical annotation and recommendations of colorectal cancer specimens on the basis of next-generation sequencing (NGS) results. (A) Distribution of actionable mutations (ie, eligible for on- or off-label use of Food and Drug Administration–approved targeted therapy or immune checkpoint inhibitor on the basis of NGS test results) demonstrated by NGS. (B) Targeted therapy and immunotherapy drugs prescribed after NGS testing. Data are reported as the name of the gene or drug (no.). (*) Mismatch repair (MMR) genes (eg, MLH1, MSH2, MSH6, PMS2). MSI-H, microsatellite instability–high.